Novartis India Limited Earnings Summary — Q1 FY2027

• Novartis India has scheduled its Board of Directors meeting for July 23, 2026, to approve unaudited results for the quarter ended June 30, 2026.
• A recent open offer by WaveRise/ChrysCapital for 64,19,608 shares at ₹860.64 saw extremely low participation, with only 40 physical shares accepted.
• The company maintains a high promoter holding of 70.68%, which has remained stable over the recent quarters.
• Domestic Institutional Investors (DII) stake saw a significant increase to 1.35% in June 2026 from 0.53% in March 2026.
• The business model continues to focus on wholesale distribution, resulting in an asset-light but import-dependent structure.
• The trading window for insiders has been closed since July 1, 2026, in anticipation of the upcoming financial results.

Management focus remains on navigating the Indian regulatory environment and maintaining alignment with the global portfolio strategy of Novartis AG, particularly in therapeutic areas like neuroscience and pain management.

Stable

The market is awaiting the formal Q1 numbers; however, the failed open offer suggests existing shareholders may be seeking valuations higher than current offer prices.

The outlook depends on the successful integration of new global parent launches into the Indian distribution network and managing price control impacts (NLEM). The company's debt-free balance sheet provides a strong safety buffer.